The FDA has approved lirafugratinib for advanced cholangiocarcinoma harboring an FGFR2 fusion or other rearrangement based on the phase 1/2 ReFocus trial.
|Videos|July 13, 2017
Management of Resectable Pancreatic Cancer
Author(s)Davendra Sohal, MD, MPH
This video examines the management of resectable pancreatic cancer, including how this type of disease is best defined, the latest standard of care in the adjuvant setting, and emerging trends in surveillance.
Advertisement
In this video, Davendra Sohal, MD, MPH, of the Cleveland Clinic in Cleveland, Ohio, discusses the management of resectable pancreatic cancer, including how this type of disease is best defined, the latest standard of care in the adjuvant setting, and emerging trends in surveillance.
Sohal spoke on this topic during an education session at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting, held last month in Chicago.
Advertisement
Related to this article
Experts preview ASTRO 2026 presentations to watch, including those on SOFT Preop, PSMAgRT, radiosurgery for depression, and AI tools for patient safety.
A prospective, multicenter study found that a blood-based miRNA assay combined with CA19-9 improved early detection of pancreatic ductal adenocarcinoma.
Beth Erickson, MD, FACR, FASTRO, FABS, discussed pioneering MRI-guided brachytherapy at MCW and her priorities as incoming ASTRO president-elect.
The FDA granted fast track designation to the oral pan-KRAS inhibitor KST-6051 for patients with KRAS-mutant advanced or metastatic solid tumors.
Advertisement
Advertisement
Trending on CancerNetwork
1
Isatuximab-Based Therapy Shows “Impressive” PFS Projections in NDMM
2
Durvalumab Plus Enfortumab Vedotin Earns FDA Priority Review in MIBC
3
The Case for Frontline Zongertinib in HER2-Mutant NSCLC
4
Subcutaneous Isatuximab Enhances Patient Experience in Multiple Myeloma
5